Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Indications & Uses
Capmaxen is indicated for:
Pharmacology
Capmatinib is a kinase inhibitor that targets MET, including the mutant variant produced by exon 14 skipping. When MET exon 14 skipping happens, the protein that results is missing a regulatory domain. Its negative regulation is reduced, so the signaling downstream of MET increases.
Capmatinib inhibited the growth of cancer cells driven by a mutant MET variant lacking exon 14, at clinically achievable concentrations. It also showed anti-tumor activity in murine tumor xenograft models derived from human lung tumors, either with a mutation leading to MET exon 14 skipping or with MET amplification. It inhibited the phosphorylation of MET triggered by binding of hepatocyte growth factor or by MET amplification. The same was true for MET mediated phosphorylation of downstream signaling proteins, and for the proliferation and survival of MET-dependent cancer cells.
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Patient Selection
Choose patients for treatment with Capmatinib based on a mutation that leads to MET exon 14 skipping, found in a tumor or plasma specimen. If the mutation isn't detected in a plasma specimen, test the tumor tissue if feasible.
Recommended Dose
The recommended dose of Capmatinib is 400 mg by mouth twice daily, with or without food. Swallow the tablets whole. Don't break, crush or chew them. If a patient misses a dose or vomits, tell them not to make up the dose but to take the next one at its scheduled time.
Side Effects
Capmatinib Hydrochloride can cause lung or breathing problems, liver problems and pancreas problems. It can also cause swelling of your hands or feet, nausea, muscle or bone pain, tiredness and weakness, and vomiting. Other side effects are trouble breathing, cough, loss of appetite and changes in certain blood tests.
Cautions & Contraindications
Warnings & Precautions
Interstitial Lung Disease (ILD): if ILD or pneumonitis is suspected, withhold Capmatinib Hydrochloride straight away. Stop it permanently if no other possible cause of the ILD or pneumonitis is found. Hepatotoxicity: check liver function tests (including ALT, AST and total bilirubin) before starting Capmatinib Hydrochloride. Repeat them every 2 weeks during the first 3 months of treatment, then once a month or as clinically indicated. Patients whose transaminases or bilirubin rise need testing more often. Depending on how severe the reaction is, withhold the medicine, reduce the dose, or stop it permanently. Pancreatic toxicity: monitor amylase and lipase at baseline and at regular intervals during treatment. Depending on the severity of the adverse drug reaction, withhold Capmatinib Hydrochloride temporarily, reduce the dose, or stop it permanently. Risk of photosensitivity: patients should be advised to limit direct ultraviolet exposure while on treatment. Embryo-fetal toxicity: animal studies and the way the medicine works show that Capmatinib Hydrochloride can cause fetal harm when given to a pregnant woman.
Use in Special Populations
Pediatric Use
Safety and effectiveness of Capmatinib Hydrochloride in pediatric patients have not been established.
Geriatric Use
In GEOMETRY mono-1, 61% of the 373 patients were 65 years or older, and 18% were 75 years or older. The safety and effectiveness seen in these patients were not different overall from those seen in younger patients.
Renal Impairment
No dose adjustment is recommended for patients with mild renal impairment (baseline creatinine clearance [CrCl] 60 to 89 mL/min by Cockcroft-Gault) or moderate renal impairment (CrCl 30 to 59 mL/min). Capmatinib Hydrochloride has not been studied in patients with severe renal impairment (CrCl 15 to 29 mL/min).
Storage
Keep Capmatinib Hydrochloride below 25°C, in a cool and dry place. Protect it from light, and keep it out of the reach of children.
Common questions about Capmaxen 200 mg
What is Capmaxen 200 mg Tablet?
Capmaxen 200 mg Tablet is a medicine that contains Capmatinib Hydrochloride. It is made by Everest Pharmaceuticals Ltd. It belongs to the Cytotoxic Chemotherapy group of medicines.
What is Capmaxen used for?
Capmaxen is used for: Cancer.
What are the side effects of Capmaxen?
Capmatinib Hydrochloride can cause lung or breathing problems, liver problems and pancreas problems. It can also cause swelling of your hands or feet, nausea, muscle or bone pain, tiredness and weakness, and vomiting.
How should I store Capmaxen?
Keep Capmatinib Hydrochloride below 25°C, in a cool and dry place. Protect it from light, and keep it out of the reach of children.
Is there a cheaper medicine with the same ingredient?
Capmaxen is already among the lowest-priced brands of Capmatinib Hydrochloride at this strength.
Do I need a prescription for Capmaxen?
Capmaxen is a prescription (Rx) medicine. Take it as your doctor advises.